PDS Biotechnology stock rises after trial meets criteria for expansion

Published 10/07/2025, 13:56
© Reuters.

Investing.com -- PDS Biotechnology Corp (NASDAQ:PDSB) stock rose 3.8% after the company announced that its clinical trial for metastatic colorectal cancer treatment has met pre-set criteria for expansion into Stage 2.

The late-stage immunotherapy company reported that patient recruitment has been completed in Stage 1 of the trial testing PDS01ADC therapeutic administered systemically in combination with floxuridine. The study, led by the National Cancer Institute (NCI), achieved the required objective response rate, with at least 6 of 9 participants experiencing a response according to RECIST v1.1 criteria.

The trial is an open-label, single-center, non-randomized Phase 2 study with three cohorts: metastatic colorectal cancer, cholangiocarcinoma, and adrenocortical cancer. While the colorectal cancer cohort will now enroll up to a total of 22 participants, the other two cohorts continue to enroll in Stage 1.

"Colorectal cancer is among the most deadly and difficult to treat cancers. In 2020, it was estimated that more than 930,000 deaths were due to colorectal cancer worldwide according to the World Health Organization, and more effective treatments are desperately needed," said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech.

The company anticipates completing patient recruitment for the metastatic colorectal cancer cohort by the fourth quarter of 2025. According to the American Cancer Society, colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with over 150,000 new cases diagnosed annually.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.